Hol olvashatok az Oncotype DX tesztel kapcsolatos tudományos cikkeket?

Az alábbi linkekre kattintva láthatja a publikációkat. (A csoportok nem feltétlenül tartalmazzák az összes elérhető cikket az egyes területekről.)

- Klinikai fejlesztés
- A terápiás döntés változása (Decision Impact)
- Neoadjuváns terápia
- Platform technológia
- A vizsgálat fejlesztése
- További Oncotype DX tesztel kapcsolatos cikkek
- Hivatkozások

Klinikai fejlesztés

• A-Multigene-Assay-to-Predict-Recurrence-of-Tamoxifen-Treated-Node-Negative-Breast-Cancer

• A Population-Based Study of Tumor Gene Expression and Risk of Breast Cancer Death Among Lymph Node-Negative Patients

• Gene Expression and Benefit of Chemotherapy in Women with Node-Negative, Estrogen Receptor-Positive Breast Cancer

• Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Breast Cancer Patients Treated with Anastrozole or Tamoxifen: A TransATAC Study

• Prognostic and Predictive Value of the 21-Gene Recurrence Score Assay in Postmenopausal, Node-Positive, Estrogen Receptor-Positive Breast Cancer

A terápiás döntés változása

• Association Between the 21-Gene Recurrence Score Assay and Risk of Locoregional Recurrence in Node-Negative, Estrogen Receptor–Positive Breast Cancer: Results From NSABP B-14 and NSABP B-20.

• Impact of a Commercial Reference Laboratory Test Recurrence Score on Decision Making in Early-Stage Breast Cancer

• Prospective Multicenter Study of the Impact of the 21-Gene Recurrence Score Assay on Medical Oncologist and Patient Adjuvant Breast Cancer Treatment Selection.

• Physician Survey of the Effect of the 21-Gene Recurrence Score Assay Results on Treatment Recommendations for Patients With Lymph Node–Positive, Estrogen Receptor–Positive Breast Cancer

Neoadjuváns terápia

• Gene Expression Profiles in Paraffin-Embedded Core Biopsy Tissue Predict Response to Chemotherapy in Women with Locally Advanced Breast Cancer

Platform technológia

• Analytical Validation of the Oncotype DX Genomic Diagnostic Test Recurrence Prognosis and Therapeutic Response Prediction in Node-Negative, Estrogen Receptor-Positive Breast Cancer

• Biomarker discovery for colon cancer using a 761 gene RT-PCR assay

• Measurement of Gene Expression in Archival Paraffin-Embedded Tissues

A vizsgálat fejlesztése

• Development and Clinical Utility of a 21-Gene Recurrence Score Prognostic Assay in Patients with Early Breast Cancer Treated with Tamoxifen

• Prognostic Role of a Multigene Reverse Transcriptase-PCR Assay in Patients with Node-Negative Breast Cancer Not Receiving Adjuvant Systemic Therapy

• Tumor Gene Expression and Prognosis in Breast Cancer Patients with 10 or More Positive Lymph Nodes

További Oncotype DX tesztel kapcsolatos cikkek

• Adjuvant Chemotherapy for Patients with Estrogen Receptor-Positive Breast Cancer

• American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer

• Development of the 21-Gene Assay and Its Application in Clinical Practice and Clinical Trials

• Estrogen- and Progesterone-Receptor Status in ECOG 2197: Comparison of Immunohistochemistry by Local and Central Laboratories and Quantitative Reverse Transcription Polymerase Chain Reaction by Central Laboratory

• Problems and Solutions in the Evaluation of Hormone Receptors in Breast Cancer

• Roadmap for Developing and Validating Therapeutically Relevant Genomic Classifiers

• Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20

Hivatkozások

1. Paik S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-pozitív breast cancer. J Clin Oncol. 2006;24(23):3726-3734.

2. Paik S, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351(27):2817-2826.

3. Data on file. Genomic Health, Redwood City, CA. 

4. Dowsett M, et al. Risk of distant recurrence using Oncotype DX in postmenopausal primary breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Abstract presented at: 31st Annual San Antonio Breast Cancer Symposium; December 10-14, 2008; San Antonio, TX. Abstract 53.

5. Harris L, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287-5312.
6. National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology^TM: breast cancer: V.1.2009. http://www.nccn.org. Published December 2, 2008. Accessed December 22, 2009.

7. Albain KS, et al; for The Breast Cancer Intergroup of North America. Prognostic and predictive value of the 21-gene Recurrence Score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010;11(1):55-65.

8. Anderson JM, et al. Molecular characterization of breast cancer core biopsy specimens by gene expression analysis using standardized quantitative RT-PCR. Poster presented at: 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX. Poster 6021.

9. Paik S, et al. Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer. J Clin Oncol. 2005;23(16S)(suppl). Abstract 510.

10. Lo SS, et al. Prospective multicenter study of the impact of the 21-gene Recurrence Score assay on medical oncologist and patient adjuvant breast cancer treatment selection [published online ahead of print January 11, 2010]. J Clin Oncol. doi:10.1200/JCO.2008.20.2119.

11. Oratz R, et al. Effect of a 21-gene reverse-transcriptase polymerase chain reaction assay on treatment recommendations for patients with lymph node-positive and estrogen receptor-positive breast cancer. Poster presented at: 32nd Annual San Antonio Breast Cancer Symposium; December 9-13, 2009; San Antonio, TX. Poster 2031.

12. Badve SS, et al. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol. 2008;26(15):2473-2481.

13. Baehner FL, et al. A Kaiser-Permanente populationbased study of ER and PR expression by the standard method, immunohistochemistry (IHC), compared to a new method, quantitative reverse transcription polymerase chain reaction (RT-PCR). Presented at: 2007 American Society of Clinical Oncology Breast Cancer Symposium; September 7-8, 2007; San Francisco, CA. Abstract 88.